Pantoprazole Olikla (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Olikla, is a proton pump inhibitor presented as a solid dosage form for oral use. It reduces stomach acid production and is used to manage acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazole Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Olikla is a proton‑pump inhibitor that acts on gastric acid secretion pathways. It is used in several acid‑related gastrointestinal conditions: - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: infrequent bowel changes.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation. - Liver enzyme elevation: signs of hepatic stress.

When prescribing Pantoprazole Olikla, consider the following safety measures: - Assess renal function: adjust use in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term users: watch for bone density loss and magnesium deficiency. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption leading to treatment failure. - Atazanavir: markedly decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Digoxin: slight rise in serum levels, watch for toxicity signs. - Methotrexate: elevated concentrations, especially at high doses. - Iron supplements: decreased iron absorption, consider timing separation.